Complement Therapeutics GmbH, a clinical-stage biotechnology company focused on complement-mediated diseases, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead gene therapy candidate, CTx001, targeting Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
The therapy had previously obtained FDA clearance to proceed with its Investigational New Drug (IND) application, enabling the program to advance into clinical development.
CTx001 is an AAV-based gene therapy engineered to deliver a truncated version of Complement Receptor 1 (mini-CR1), with the potential to modulate both classical and alternative pathways of the complement system. GA is an advanced form of dry AMD that leads to irreversible vision loss and currently has limited treatment options.
The FDA’s Fast Track designation is designed to expedite the development and review of therapies for serious conditions with unmet medical needs, enabling more frequent interactions with regulators and faster patient access.
CTx001 will be evaluated in the Opti-GAIN (Optimised Geographic Atrophy Interventional) first-in-human Phase I/II clinical trial, with the first patient dosing expected in the United States in Q1 2026.
